Q3 Earnings Forecast for ZNTL Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised down its Q3 2025 EPS estimate for Zentalis Pharmaceuticals to ($0.51) per share, down from a previous forecast of ($0.43).
• Zentalis Pharmaceuticals reported Q3 earnings of ($0.37) per share, which was better than analysts' consensus estimate of ($0.56).
• Current analyst ratings for Zentalis Pharmaceuticals include four "hold" ratings, two "buy" ratings, and one "strong buy" rating, with an average price target of $8.20.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.51) for the quarter, down from their previous estimate of ($0.43). The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals' Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($1.88) EPS and FY2027 earnings at ($1.77) EPS.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 7th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. Finally, Wedbush reiterated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $8.20.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL traded up $0.09 during trading hours on Monday, reaching $1.50. The company's stock had a trading volume of 496,995 shares, compared to its average volume of 1,237,260. The firm has a market capitalization of $107.85 million, a price-to-earnings ratio of -0.66 and a beta of 1.71. The firm has a 50-day simple moving average of $1.38 and a 200-day simple moving average of $1.54. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.19.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently modified their holdings of ZNTL. Raymond James Financial Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $68,000. JPMorgan Chase & Co. increased its position in shares of Zentalis Pharmaceuticals by 75.7% in the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock valued at $2,605,000 after acquiring an additional 370,511 shares during the period. Franklin Resources Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $323,000. Geode Capital Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock valued at $3,979,000 after purchasing an additional 20,864 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock valued at $105,000 after purchasing an additional 7,305 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.